The latest price target for BioLife Solns (NASDAQ:BLFS) was reported by HC Wainwright & Co. on November 18, 2024. The analyst firm set a price target for $27.00 expecting BLFS to rise to within 12 months (a possible 8.96% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for BioLife Solns (NASDAQ:BLFS) was provided by HC Wainwright & Co., and BioLife Solns maintained their buy rating.

The last upgrade for BioLife Solutions Inc happened on May 13, 2024 when Benchmark raised their price target to $25. Benchmark previously had a hold for BioLife Solutions Inc.

There is no last downgrade for BioLife Solns.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLife Solns, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLife Solns was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest BioLife Solns (BLFS) rating was a maintained with a price target of $29.00 to $27.00. The current price BioLife Solns (BLFS) is trading at is $24.78, which is out of the analyst’s predicted range.